Bio­gen slams cov­er­age pro­pos­al for amy­loid-tar­get­ed Alzheimer's drugs in 31-page com­ment

With about two months left be­fore the Cen­ters for Medicare and Med­ic­aid Ser­vices fi­nal­izes its cov­er­age de­ci­sion on amy­loid-tar­get­ed Alzheimer’s drugs, Bio­gen on Thurs­day closed out the com­ment pe­ri­od with an­oth­er push to re­verse the re­stric­tive cov­er­age pro­pos­al.

The com­pa­ny sub­mit­ted a 31-page com­ment to­day, rail­ing against the CMS draft and call­ing for ma­jor changes be­fore it’s fi­nal­ized in April. Al­most 7,000 com­ments have now been filed on the NCD, many of them sup­port­ive of CMS’ pro­pos­al, which calls for an ad­di­tion­al ran­dom­ized con­trolled tri­al be­fore wider cov­er­age for Bio­gen’s Aduhelm (ad­u­canum­ab).

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER